ximelagatran and its Impurities
Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke. It is an anticoagulant. Reference standards of Ximelagatran API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
1-((2R)-2-Amino-2-cyclohexylacetyl)-N-(4’-cyanobenzyl)-2-L-azetidinecarboxamide-d11
1-((2R)-2-Amino-2-cyclohexylacetyl)-N-(4’-cyanobenzyl)-2-L-azetidinecarboxamide-d11
Catalogue No.:PA STI 005650
CAS :
1356930-51-2
Molecular Formula : C20H15D11N4O2
Molecular Weight : 365.51
1-[(2R)-N'-Boc-2-amino-2-cyclohexylacetyl]-N-(4'-cyanobenzyl)-2-L-azetidinecarboxamide-d11
1-[(2R)-N'-Boc-2-amino-2-cyclohexylacetyl]-N-(4'-cyanobenzyl)-2-L-azetidinecarboxamide-d11
Catalogue No.:PA STI 013790
CAS :
1356352-32-3
Molecular Formula : C25H23D11N4O4
Molecular Weight : 465.63
